Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Identifying differentially methylated sites in samples with varying tumor purity.

Häkkinen A, Alkodsi A, Facciotto C, Zhang K, Kaipio K, Leppä S, Carpén O, Grénman S, Hynninen J, Hietanen S, Lehtonen R, Hautaniemi S.

Bioinformatics. 2018 Sep 15;34(18):3078-3085. doi: 10.1093/bioinformatics/bty310.

PMID:
29912358
2.

A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.

Tumiati M, Hietanen S, Hynninen J, Pietilä E, Färkkilä A, Kaipio K, Roering P, Huhtinen K, Alkodsi A, Li Y, Lehtonen R, Erkan EP, Tuominen MM, Lehti K, Hautaniemi SK, Vähärautio A, Grénman S, Carpén O, Kauppi L.

Clin Cancer Res. 2018 Sep 15;24(18):4482-4493. doi: 10.1158/1078-0432.CCR-17-3770. Epub 2018 Jun 1.

PMID:
29858219
3.

Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer.

Kozłowska E, Färkkilä A, Vallius T, Carpén O, Kemppainen J, Grénman S, Lehtonen R, Hynninen J, Hietanen S, Hautaniemi S.

Cancer Res. 2018 Jul 15;78(14):4036-4044. doi: 10.1158/0008-5472.CAN-17-3746. Epub 2018 May 16.

PMID:
29769198
4.

Clinical Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Response Evaluation after Primary Treatment of Advanced Epithelial Ovarian Cancer.

Hynninen J, Laasik M, Vallius T, Kemppainen J, Grönroos S, Virtanen J, Casado J, Hautaniemi S, Grenman S, Seppänen M, Auranen A.

Clin Oncol (R Coll Radiol). 2018 Aug;30(8):507-514. doi: 10.1016/j.clon.2018.04.007. Epub 2018 May 9.

PMID:
29753662
5.

18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

Vallius T, Hynninen J, Kemppainen J, Alves V, Auranen K, Matomäki J, Oksa S, Virtanen J, Grénman S, Auranen A, Seppänen M.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1224-1232. doi: 10.1007/s00259-018-3961-z. Epub 2018 Feb 23.

PMID:
29476227
6.

Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.

Nguyen EV, Huhtinen K, Goo YA, Kaipio K, Andersson N, Rantanen V, Hynninen J, Lahesmaa R, Carpen O, Goodlett DR.

Mol Cell Proteomics. 2017 Jul;16(7):1377-1392. doi: 10.1074/mcp.M116.058321. Epub 2017 Apr 28.

7.

Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.

Vallius T, Hynninen J, Auranen A, Matomäki J, Oksa S, Roering P, Grènman S.

Tumour Biol. 2017 Feb;39(2):1010428317691189. doi: 10.1177/1010428317691189.

PMID:
28218038
8.

Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Müllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors.

Haltia UM, Hallamaa M, Tapper J, Hynninen J, Alfthan H, Kalra B, Ritvos O, Heikinheimo M, Unkila-Kallio L, Perheentupa A, Färkkilä A.

Gynecol Oncol. 2017 Jan;144(1):83-89. doi: 10.1016/j.ygyno.2016.11.018. Epub 2016 Nov 18.

PMID:
27871721
9.

A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.

Gidwani K, Huhtinen K, Kekki H, van Vliet S, Hynninen J, Koivuviita N, Perheentupa A, Poutanen M, Auranen A, Grenman S, Lamminmäki U, Carpen O, van Kooyk Y, Pettersson K.

Clin Chem. 2016 Oct;62(10):1390-400. doi: 10.1373/clinchem.2016.257691. Epub 2016 Aug 18.

10.

REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.

Lehtinen L, Vesterkvist P, Roering P, Korpela T, Hattara L, Kaipio K, Mpindi JP, Hynninen J, Auranen A, Davidson B, Haglund C, Iljin K, Grenman S, Siitari H, Carpen O.

PLoS One. 2016 Mar 16;11(3):e0151590. doi: 10.1371/journal.pone.0151590. eCollection 2016.

11.

Differentially Expressed in Chondrocytes 2 (DEC2) Increases the Expression of IL-1β and Is Abundantly Present in Synovial Membrane in Rheumatoid Arthritis.

Olkkonen J, Kouri VP, Hynninen J, Konttinen YT, Mandelin J.

PLoS One. 2015 Dec 28;10(12):e0145279. doi: 10.1371/journal.pone.0145279. eCollection 2015.

12.

18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Vallius T, Peter A, Auranen A, Carpén O, Kemppainen J, Matomäki J, Oksa S, Roering P, Seppänen M, Grénman S, Hynninen J.

Gynecol Oncol. 2016 Jan;140(1):29-35. doi: 10.1016/j.ygyno.2015.10.018. Epub 2015 Oct 26.

PMID:
26515076
13.

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.

Chen P, Huhtinen K, Kaipio K, Mikkonen P, Aittomäki V, Lindell R, Hynninen J, Auranen A, Grénman S, Lehtonen R, Carpén O, Hautaniemi S.

Cancer Res. 2015 Aug 1;75(15):2987-98. doi: 10.1158/0008-5472.CAN-14-3242. Epub 2015 Jun 29.

14.

Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.

Vallius T, Hynninen J, Auranen A, Carpén O, Matomäki J, Oksa S, Virtanen J, Grénman S.

Tumour Biol. 2014 Dec;35(12):12389-95. doi: 10.1007/s13277-014-2553-1. Epub 2014 Sep 5.

PMID:
25190018
15.

A prospective comparison of integrated FDG-PET/contrast-enhanced CT and contrast-enhanced CT for pretreatment imaging of advanced epithelial ovarian cancer.

Hynninen J, Kemppainen J, Lavonius M, Virtanen J, Matomäki J, Oksa S, Carpén O, Grénman S, Seppänen M, Auranen A.

Gynecol Oncol. 2013 Nov;131(2):389-94. doi: 10.1016/j.ygyno.2013.08.023. Epub 2013 Aug 29.

PMID:
23994535
16.

Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?

Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A.

Gynecol Oncol. 2013 Feb;128(2):229-32. doi: 10.1016/j.ygyno.2012.11.007. Epub 2012 Nov 9.

PMID:
23142076
17.

FDG PET/CT in staging of advanced epithelial ovarian cancer: frequency of supradiaphragmatic lymph node metastasis challenges the traditional pattern of disease spread.

Hynninen J, Auranen A, Carpén O, Dean K, Seppänen M, Kemppainen J, Lavonius M, Lisinen I, Virtanen J, Grénman S.

Gynecol Oncol. 2012 Jul;126(1):64-8. doi: 10.1016/j.ygyno.2012.04.023. Epub 2012 Apr 24.

PMID:
22542580
18.

Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer.

Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppänen M, Grénman S.

Int J Gynecol Cancer. 2011 Dec;21(9):1573-8. doi: 10.1097/IGC.0b013e3182225509.

PMID:
21811175
19.

Opinion comparison concerning future information technology in Finnish community pharmacies.

Westerling AM, Hynninen JT, Haikala VE, Airaksinen MS.

Pharm World Sci. 2010 Dec;32(6):787-94. doi: 10.1007/s11096-010-9438-1. Epub 2010 Sep 17.

PMID:
20848207

Supplemental Content

Loading ...
Support Center